Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitors for ICI-related Dermatitis in Solid Tumor Patients
NCT06715982Phase 2Recruiting
- Sponsor
- Hangzhou Cancer Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, open-label trial in dermatitis, sponsored by Hangzhou Cancer Hospital. Primary endpoint: Safety of JAK inhibitors. Started Dec 2024; status: recruiting.
02
Conditions
dermatitis
Beyond the preview
Go deeper on NCT06715982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06715982.